ribosomal protein L35Genealiases: DBA19 · L35 · uL29
Q-omics provides the consensus-scored RPL35 profile across patient tissues and cancer cell-line models. RPL35 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL35 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RPL35 protein abundance shows 24,624 significant protein co-abundance associations, with the highest sampling consensus in COAD. Together, these results highlight ACC, KIRC, and COAD as cancer lineages where RPL35 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL35 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL35 survival associations across molecular data types. RPL35 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL35 RNA expression–survival associations across cancer types. High RPL35 expression shows unfavorable associations in ACC, LIHC, KIRC, HNSC and KIRP, but favorable associations in CHOL. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL35 RNA expression.
This table summarizes RPL35 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RPL35. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL35 shows higher tumor expression in KIRC, COAD, KIRP, LIHC, HNSC and LUSC. The KIRC box plot shows higher RPL35 RNA expression in tumor versus normal tissue (log2 FC = +0.949, t-test p < 0.001).
This table shows molecular features associated with RPL35 in patient tissues and cancer cell lines. In patient samples, RPL35 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL35 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
